Traditional cancer research has long relied upon 2D cell cultures grown on plastic substrates, a method that oversimplifies the tumor microenvironment and often fails to capture the intricacies of tumor behavior. These limitations have spurred a shift towards organoids — 3D cultures that maintain architectural and cellular heterogeneity, offering a more faithful replication of in vivo conditions. The newly developed pediatric brain tumor organoids provide an unprecedented platform upon which researchers can conduct drug screening with remarkable accuracy, circumventing the ethical and practical dilemmas of testing treatments directly on young patients.

Professor Luca Tiberi, who leads this study within the Department of Cellular, Computational and Integrative Biology at the University of Trento, explains the model’s ingenuity: it acts as a “tumor avatar,” faithfully replicating the tumor’s biology and allowing researchers to examine therapy efficacy in a controlled environment. Unlike previous models, these patient-derived organoids (PDOs), or tumoroids, preserve the native molecular landscape and phenotypic complexity of pediatric brain tumors, such as ependymoma and medulloblastoma, two of the most aggressive and prevalent malignant tumors in children’s brains.

The generation of these tumoroids begins with biopsies obtained during clinical procedures, ensuring that the resulting organoids are patient-specific and retain the nuanced cellular heterogeneity of the original tumor. This is a critical advancement, as it addresses the major drawbacks of both 2D cultures—which tend to lose cellular diversity—and organoids derived from induced pluripotent stem cells (iPSCs), which do not entirely capture the disease’s complexity at a cellular and molecular level.

By maintaining the structural and phenotypic fidelity of the tumors, these organoids offer remarkable insights into tumor biology. They reproduce the tumor microenvironment’s dynamics, including cell-to-cell interactions and extracellular matrix composition, which are vital for understanding tumor growth and drug resistance mechanisms. This structural complexity enables a broader and more nuanced pharmacological screening, making it possible to identify promising therapeutic agents with higher translational relevance.

The contribution of Bambino Gesù Children’s Hospital has been instrumental in this endeavor. Patient biopsies collected under stringent clinical protocols have provided the raw biological material essential for creating these tumoroids. Additionally, the hospital’s expertise in clinical characterization has enriched the model’s development, ensuring its alignment with real-world pathological and therapeutic challenges faced by pediatric oncology.

These developments not only foster a better understanding of tumor biology but also offer a scalable and reproducible protocol for the wider scientific community. Published in a high-impact journal like Nature Protocols, the methodology is poised to become a standard reference, enabling researchers worldwide to adopt this technology for preclinical studies. This accessibility accelerates collaborative efforts to discover novel treatments, potentially revolutionizing pediatric neuro-oncology research.

The implications of the tumoroid platform extend beyond drug efficacy testing. By serving as a dynamic and manipulable in vitro system, these organoids allow deep exploration of tumor genetics, signaling pathways, and microenvironmental influences. This opens avenues for identifying biomarkers predictive of treatment response and resistance, ultimately informing personalized medicine strategies tailored to individual patients’ tumors.

Despite these advances, researchers remain vigilant in expanding the utility of organoid models to cover a broader spectrum of pediatric brain tumors. Efforts are already underway to adapt these robust protocols for less aggressive neoplasms such as low-grade gliomas. This dedication ensures that the benefits of innovative modeling techniques can percolate through all aspects of pediatric brain cancer research, fostering comprehensive therapeutic innovations.

The research team, including dedicated PhD students at Cibio Department, has made substantial contributions through meticulous experimentation and characterization efforts. Their work embodies the synergy of computational biology, cellular dynamics, and clinical expertise, emphasizing the multidisciplinary nature of modern cancer research.

Importantly, these advancements resonate profoundly within the clinical community, as they offer hope for accelerating the development of effective, less toxic therapies. With tumoroids mirroring patient tumors’ biology more closely than ever before, the potential to reduce trial-and-error drug administration in children shines as a beacon of hope, promising more personalized and efficient treatment regimens.

In summary, the advent of patient-derived ependymoma and medulloblastoma tumoroids constitutes a paradigm shift in pediatric neuro-oncology research. Through sophisticated 3D modeling, preservation of tumor complexity, and a direct link to clinical samples, this platform sets a new standard for drug screening and disease understanding. It exemplifies how cutting-edge biological engineering can bridge laboratory research and clinical application, transforming the landscape of pediatric brain tumor treatment and nurturing the promise of better outcomes for vulnerable young patients worldwide.

Subject of Research: Human tissue samples

Article Title: Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening

News Publication Date: 30-Mar-2026

Web References:
https://doi.org/10.1038/s41596-026-01347-9

References:
Tiberi, L., Lago, C., Leva, G., Kool, M., & Miele, E. (2026). Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening. Nature Protocols. https://doi.org/10.1038/s41596-026-01347-9

Keywords: Pediatric brain tumors, tumor organoids, patient-derived tumoroids, medulloblastoma, ependymoma, drug screening, 3D models, pediatric neuro-oncology, preclinical pharmacology, tumor heterogeneity, disease modeling, personalized therapy

Traditionally, the World Health Organization’s classification of CNS tumors has emphasized the distinctive genetic expression patterns that define tumor subtypes, with FOXR2 gene activation considered a hallmark specific to neuroblastoma within the CNS. Neuroblastoma is a type of embryonal tumor primarily affecting children, known for exhibiting relatively favorable responses to multimodal therapy. However, the investigative team led by Dr. Jason Cheng-Hsuan Chiang, MD, PhD, of St. Jude’s Department of Pathology, encountered a recurrent brain tumor in a pediatric patient that defied this classification. The tumor exhibited FOXR2 activation despite not being a neuroblastoma, prompting a comprehensive genomic investigation into FOXR2’s role in other brain tumor entities.

Leveraging the extensive genomic datasets housed within the St. Jude Cloud — a rich repository encompassing whole genome, whole exome, and transcriptome (RNA) sequencing data from a large cohort of pediatric patients — the researchers conducted a systematic search for FOXR2 activation signatures across various tumor types. The results were striking: among 41 patients, 42 tumors demonstrated FOXR2 activation, but only 11 conformed to the expected classification of CNS neuroblastoma. The remaining 31 tumors comprised a heterogeneous group that included high-grade gliomas, pineoblastomas, and several other rare embryonal tumors. This broader occurrence of FOXR2 activation across multiple tumor types suggests a heretofore unrecognized molecular commonality that transcends traditional diagnostic boundaries.

High-grade gliomas, for instance, represent some of the most aggressive malignant brain tumors in pediatric populations, frequently associated with dismal clinical outcomes and limited treatment options. The identification of FOXR2 activation in such malignancies is particularly alarming, given the oncogene’s putative role in promoting tumorigenicity through mechanisms that remain to be fully elucidated. FOXR2 belongs to the forkhead box family of transcription factors, which are known to regulate critical cellular processes including proliferation, differentiation, and survival. Aberrant activation of FOXR2 may thus drive oncogenic pathways that fuel tumor growth and resistance to therapy, underscoring the urgency of understanding the functional consequences of its expression in diverse tumor contexts.

Clinically, the differentiation between CNS tumor subtypes guides therapeutic decisions and prognostic counseling. Emily Hanzlik, MD, co-first author and researcher at St. Jude’s Department of Pediatric Medicine, highlights the stark divergence in outcomes observed within the cohort: while pediatric CNS neuroblastomas with FOXR2 activation responded favorably to aggressive multimodal treatment approaches encompassing surgery, chemotherapy, and radiation, other FOXR2-positive tumors, notably high-grade gliomas and pineoblastomas, displayed poor responses and reduced survival rates. This clinical heterogeneity challenges the notion of using FOXR2 activation as a solitary biomarker and advocates for integrative diagnostic strategies that combine molecular profiling with histopathological and imaging data.

On a molecular diagnostic level, one of the significant hurdles has been the difficulty in reliably detecting the genomic alterations that lead to FOXR2 activation using standard assays. The research team’s meticulous interrogation of complex genomic data revealed diverse and cryptic mechanisms underpinning FOXR2 upregulation, including structural variants and subtle genomic rearrangements undetectable by conventional methods. Co-first author Dr. Alexa Siskar, PhD, from St. Jude’s Department of Pathology, emphasizes that uncovering these intricate genomic events opens new avenues for diagnostic refinement and precision medicine, enabling clinicians to identify FOXR2 activation across a spectrum of tumor types with greater accuracy.

This revelation underscores the broader imperative within neuro-oncology to aggregate multifaceted data layers—encompassing DNA and RNA sequencing results, detailed histologic examination, and advanced neuroimaging—to yield a comprehensive understanding of tumor biology. Dr. Chiang stresses that a holistic diagnostic paradigm is indispensable for delineating tumor subtypes, predicting clinical trajectories, and customizing therapeutic regimens to achieve optimal outcomes. As such, the once seemingly straightforward link between FOXR2 activation and CNS neuroblastoma has become a multidimensional puzzle prompting a reassessment of both laboratory and clinical practices.

The study’s findings accession from St. Jude’s extensive patient data repository highlight the transformative potential of integrating high-resolution genomic data with clinical observation to unveil rare and previously uncharacterized oncogenic phenomena. Ultimately, these insights may translate to more precise molecular stratification of pediatric brain tumors, guiding the development of targeted therapies and improving patient prognoses. As knowledge accrues about FOXR2’s oncogenic roles across distinct tumor types, the research community anticipates novel opportunities to interfere with its function therapeutically.

Moreover, the confirmation that FOXR2 is activated in a wider group of pediatric brain tumors raises vital questions about the underlying molecular drivers and their interactions with tumor microenvironments. The heterogeneity of genetic alterations leading to FOXR2 activation hints at complex regulatory networks, with potential involvement of epigenetic modifications and cooperation with other oncogenic pathways. Decoding this regulatory circuitry is essential for understanding tumor genesis and identifying vulnerabilities amenable to pharmacologic intervention.

In the emerging landscape of pediatric neuro-oncology, embracing such nuanced molecular insights challenges longstanding diagnostic orthodoxy and exemplifies the shift toward precision oncology. As Dr. Hanzlik notes, the implications extend beyond academic comprehension to real-world patient care: better molecular characterization ensures that pediatric patients receive accurately tailored therapies aligned with the biological behavior of their tumors, thereby maximizing efficacy while minimizing unnecessary toxicity.

Funding for this pivotal research was provided through grants from prominent institutions including the National Cancer Institute, the V Foundation for Cancer Research, and ALSAC—the fundraising arm of St. Jude Children’s Research Hospital—reinforcing the hospital’s commitment to advancing cutting-edge pediatric cancer biology. Collaborative efforts involving multiple institutions and investigators have enriched the study’s breadth and impact, underscoring the importance of interdisciplinary cooperation in unraveling complex oncologic phenomena.

St. Jude Children’s Research Hospital, a uniquely dedicated pediatric oncology center recognized as a National Cancer Institute-designated Comprehensive Cancer Center, continues to spearhead innovative research that revolutionizes the understanding, diagnosis, and treatment of childhood cancers. Its leadership in pediatric cancer genomics contributes to elevating survival rates and improving quality of life for patients worldwide, demonstrating how integrating molecular science with clinical care can resonate on a global scale.

As the scientific community digests these critical findings about FOXR2 activation’s broader roles, future research directions include validating these observations in larger cohorts, exploring therapeutic targeting of FOXR2 pathways, and refining molecular diagnostics to incorporate newly discovered genomic alterations. This landmark study illustrates the dynamic nature of cancer biology and the ongoing quest to decode its complexities to benefit patients—a pursuit that remains at the heart of St. Jude’s mission.

Subject of Research: Pediatric Brain Tumors and FOXR2 Oncogene Activation

Article Title: FOXR2 activation is not exclusive of CNS neuroblastoma

News Publication Date: 15-Apr-2025

Web References:

• St. Jude Cloud
• Neuro-Oncology Journal Article
• St. Jude Research Laboratory – Jason Chiang
• St. Jude Department of Pathology
• St. Jude Department of Pediatric Medicine
• St. Jude Children’s Research Hospital

References:
Chiang J.C-H., Hanzlik E., Siskar A., et al. FOXR2 activation is not exclusive of CNS neuroblastoma. Neuro-Oncology, 2025. DOI: 10.1093/neuonc/noaf076.

Image Credits: St. Jude Children’s Research Hospital

Keywords: Brain tumors, Neuroblastoma, Central nervous system, Oncogenes, Cancer genomics, FOXR2 activation, Pediatric oncology, High-grade gliomas, Pineoblastomas, Genomic diagnostics, Pediatric brain cancer, Molecular pathology